title: miRNA let-7b modulates macrophage polarization and enhances tumor-associated macrophages to promote angiogenesis and mobility in prostate cancer.
abstract: Macrophage polarization is a highly plastic physiological process that responds to a variety of environmental factors by changing macrophage phenotype and function. Tumor-associated macrophages (TAMs) are generally recognized as promoting tumor progression. As universal regulators, microRNAs (miRNAs) are functionally involved in numerous critical cellular processes including macrophage polarization. Let-7b, a miRNA, has differential expression patterns in inflamed tissues compared with healthy controls. However, whether and how miRNA let-7b regulates macrophage phenotype and function is unclear. In this report, we find that up-regulation of let-7b is characteristic of prostatic TAMs, and down-regulation of let-7b in TAMs leads to changes in expression profiles of inflammatory cytokines, such as IL-12, IL-23, IL-10 and TNF-α. As a result, TAMs treated with let-7b inhibitors reduce angiogenesis and prostate carcinoma (PCa) cell mobility. Let-7b may play a vital role in regulating macrophage polarization, thus modulating the prognosis of prostate cancer.
authors.affiliation: Institute of Immunotherapy of Nanchang University, and Jiangxi Academy of Medical Sciences, Nanchang, China.|Jiangxi Provincial Key Laboratory of Immunotherapy, Nanchang, China.
authors.forename: Zhigang
authors.initials: Z
authors.lastname: Wang
authors.affiliation: Institute of Immunotherapy of Nanchang University, and Jiangxi Academy of Medical Sciences, Nanchang, China.|Jiangxi Provincial Key Laboratory of Immunotherapy, Nanchang, China.
authors.forename: Lu
authors.initials: L
authors.lastname: Xu
authors.affiliation: Institute of Immunotherapy of Nanchang University, and Jiangxi Academy of Medical Sciences, Nanchang, China.|Jiangxi Provincial Key Laboratory of Immunotherapy, Nanchang, China.
authors.forename: Yinying
authors.initials: Y
authors.lastname: Hu
authors.affiliation: Institute of Immunotherapy of Nanchang University, and Jiangxi Academy of Medical Sciences, Nanchang, China.|Jiangxi Provincial Key Laboratory of Immunotherapy, Nanchang, China.
authors.forename: Yanqin
authors.initials: Y
authors.lastname: Huang
authors.affiliation: Institute of Immunotherapy of Nanchang University, and Jiangxi Academy of Medical Sciences, Nanchang, China.|Jiangxi Provincial Key Laboratory of Immunotherapy, Nanchang, China.
authors.forename: Yujuan
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Departments of Surgery, Pathology, and Oncology, University of Western Ontario, London, Canada.
authors.forename: Xiufen
authors.initials: X
authors.lastname: Zheng
authors.affiliation: Institute of Immunotherapy of Nanchang University, and Jiangxi Academy of Medical Sciences, Nanchang, China.|Jiangxi Provincial Key Laboratory of Immunotherapy, Nanchang, China.
authors.forename: Shanshan
authors.initials: S
authors.lastname: Wang
authors.affiliation: Institute of Immunotherapy of Nanchang University, and Jiangxi Academy of Medical Sciences, Nanchang, China.|Jiangxi Provincial Key Laboratory of Immunotherapy, Nanchang, China.
authors.forename: Yifan
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Institute of Immunotherapy of Nanchang University, and Jiangxi Academy of Medical Sciences, Nanchang, China.|Jiangxi Provincial Key Laboratory of Immunotherapy, Nanchang, China.
authors.forename: Yanrong
authors.initials: Y
authors.lastname: Yu
authors.affiliation: Institute of Immunotherapy of Nanchang University, and Jiangxi Academy of Medical Sciences, Nanchang, China.|Jiangxi Provincial Key Laboratory of Immunotherapy, Nanchang, China.
authors.forename: Meng
authors.initials: M
authors.lastname: Zhang
authors.affiliation: Institute of Immunotherapy of Nanchang University, and Jiangxi Academy of Medical Sciences, Nanchang, China.|Jiangxi Provincial Key Laboratory of Immunotherapy, Nanchang, China.
authors.forename: Keng
authors.initials: K
authors.lastname: Yuan
authors.affiliation: Institute of Immunotherapy of Nanchang University, and Jiangxi Academy of Medical Sciences, Nanchang, China.|Jiangxi Provincial Key Laboratory of Immunotherapy, Nanchang, China.|Departments of Surgery, Pathology, and Oncology, University of Western Ontario, London, Canada.
authors.forename: Weiping
authors.initials: W
authors.lastname: Min
mesh_terms: D015703:Antigens, CD / Q000378:metabolism; D063646:Carcinogenesis / Q000473:pathology; D002454:Cell Differentiation; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000235:genetics; D016764:Cell Polarity; D049109:Cell Proliferation; D016207:Cytokines / Q000378:metabolism; D015536:Down-Regulation / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic; D061307:Human Umbilical Vein Endothelial Cells / Q000378:metabolism; D006801:Humans; D007249:Inflammation / Q000473:pathology; D008264:Macrophages / Q000378:metabolism* / Q000473:pathology*; D008297:Male; D035683:MicroRNAs / Q000235:genetics / Q000378:metabolism*; D009361:Neoplasm Invasiveness; D009389:Neovascularization, Pathologic / Q000235:genetics*; D010641:Phenotype; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000473:pathology*; D015854:Up-Regulation / Q000235:genetics
chemical_list: D015703:Antigens, CD; D016207:Cytokines; D035683:MicroRNAs; C487931:mirnlet7 microRNA, human